Profile data is unavailable for this security.
About the company
Avacta Group plc is a United Kingdom-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. The Company has two segments: Therapeutics and Diagnostics. The Therapeutics segment is a clinical stage oncology biotech division harnessing therapeutic platforms to develop novel, highly targeted cancer drugs. The Diagnostics segment is focused on supporting healthcare professionals and broadening access to diagnostics. It has two platforms: preICISION and Affimer. The Company's preICISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preICISION platform harnesses this tumor specific protease to activate preICISION peptide drug conjugates and preICISION antibody/Affimer drug conjugates in the tumor microenvironment. Its lead preICISION program AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies.
- Revenue in GBP (TTM)23.25m
- Net income in GBP-24.95m
- Incorporated2003
- Employees154.00
- LocationAvacta Group PLCUnit 20, Ash WayWETHERBY LS23 7FAUnited KingdomGBR
- Phone+44 190 421 7070
- Fax+44 844 414 0453
- Websitehttps://avacta.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Poolbeg Pharma PLC | 0.00 | -3.93m | 48.75m | 8.00 | -- | 3.38 | -- | -- | -0.0079 | -0.0079 | 0.00 | 0.0289 | 0.00 | -- | -- | 0.00 | -22.65 | -- | -24.00 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 16.11 | -- | -- | -- |
| Futura Medical PLC | 8.40m | -3.75m | 108.37m | 12.00 | -- | 13.88 | -- | 12.90 | -0.0126 | -0.0126 | 0.0272 | 0.0259 | 0.8538 | 5,710.27 | 7.20 | 699,850.80 | -38.14 | -79.25 | -47.43 | -127.22 | 67.70 | -- | -44.68 | -914.37 | 3.75 | -- | 0.00 | -- | -- | -- | -11.40 | -- | 219.68 | -- |
| Scancell Holdings Plc | 0.00 | -11.32m | 137.12m | 51.00 | -- | -- | -- | -- | -0.0138 | -0.0138 | 0.00 | -0.0102 | 0.00 | -- | -- | 0.00 | -37.31 | -33.32 | -40.52 | -35.82 | -- | -- | -- | -817.98 | -- | -- | 1.73 | -- | -- | -- | -161.24 | -- | 77.85 | -- |
| 4Basebio PLC | 506.00k | -7.67m | 179.35m | -- | -- | -- | -- | 354.45 | -0.6222 | -0.6222 | 0.0411 | -0.0399 | 0.0429 | 0.714 | 6.29 | -- | -64.93 | -- | -77.36 | -- | 67.19 | -- | -1,514.82 | -- | 2.06 | -26.66 | 1.05 | -- | 88.81 | -- | -48.83 | -- | -- | -- |
| hVIVO PLC | 64.38m | 17.45m | 197.65m | 274.00 | 11.69 | 5.22 | 9.56 | 3.07 | 0.0252 | 0.0252 | 0.0932 | 0.0565 | 0.9242 | -- | 4.25 | 234,974.50 | 25.04 | -0.643 | 46.68 | -1.29 | -- | -- | 27.10 | -0.765 | 1.60 | -- | 0.2530 | -- | 15.61 | 35.40 | 2,176.68 | -- | 136.55 | -- |
| Bioventix PLC | 13.60m | 8.67m | 200.96m | 16.00 | 23.58 | 17.57 | 22.87 | 14.78 | 1.63 | 1.63 | 2.56 | 2.19 | 1.09 | 1.53 | 2.54 | 849,780.60 | 69.72 | 56.43 | 79.03 | 61.01 | 93.75 | 92.64 | 63.73 | 65.08 | 6.69 | -- | 0.00 | 84.49 | 9.36 | 7.93 | 9.10 | 8.13 | -37.12 | 20.03 |
| Avacta Group Plc | 23.25m | -24.95m | 219.11m | 154.00 | -- | -- | -- | 9.43 | -0.0914 | -0.0914 | 0.0853 | -- | -- | -- | -- | 150,954.50 | -- | -- | -- | -- | 48.37 | -- | -107.31 | -- | -- | -0.575 | -- | -- | 140.83 | -- | 32.54 | -- | -- | -- |
| Faron Pharmaceuticals Oy | 0.00 | -26.49m | 224.94m | 34.00 | -- | 194.67 | -- | -- | -0.3183 | -0.3183 | 0.00 | 0.011 | 0.00 | -- | -- | 0.00 | -130.90 | -213.06 | -443.92 | -963.12 | -- | -- | -- | -- | -- | -5.99 | 0.9022 | -- | -- | -- | -7.71 | -- | -16.05 | -- |
| Allergy Therapeutics plc | 53.26m | -50.22m | 226.41m | 635.00 | -- | 8.56 | -- | 4.25 | -0.0266 | -0.0266 | 0.017 | 0.0056 | 0.7571 | 2.21 | 4.92 | 83,870.87 | -71.39 | -11.59 | -102.10 | -15.15 | 52.54 | 70.08 | -94.29 | -11.78 | 0.9281 | -7.93 | 0.2713 | -- | -18.11 | -2.71 | -212.65 | -- | 16.41 | -- |
| Puretech Health PLC | 351.32k | -61.91m | 340.91m | 90.00 | -- | 1.44 | -- | 970.37 | -0.2258 | -0.2258 | 0.0013 | 0.9904 | 0.0007 | -- | 0.2252 | 3,903.59 | -14.13 | 4.92 | -16.35 | 5.94 | -- | -- | -19,222.22 | 352.67 | -- | -- | 0.0728 | 0.00 | -78.68 | -30.64 | -30.47 | -- | -44.10 | -- |
| Oxford BioMedica plc | 89.54m | -157.49m | 376.07m | 714.00 | -- | 4.67 | -- | 4.20 | -1.63 | -1.63 | 0.9273 | 0.7645 | 0.2513 | 3.91 | 3.07 | 125,404.80 | -51.69 | -19.60 | -64.26 | -24.68 | 44.37 | 50.74 | -205.68 | -44.38 | 2.90 | -22.92 | 0.5888 | -- | -36.04 | 6.04 | -302.20 | -- | -0.6307 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Hargreaves Lansdown Asset Management Ltd.as of 01 Jul 2024 | 26.04m | 7.25% |
| Jarvis Investment Management Ltd.as of 01 Jul 2024 | 21.73m | 6.05% |
| Conifer Management LLCas of 28 Apr 2023 | 11.85m | 3.30% |
| Baillie Gifford & Co.as of 28 Apr 2023 | 10.12m | 2.82% |
| IG Markets Ltd.as of 01 Jul 2024 | 8.71m | 2.43% |
| HSBC Global Asset Management (UK) Ltd.as of 01 Jul 2024 | 6.27m | 1.75% |
| AXA Investment Managers UK Ltd.as of 31 Jul 2024 | 4.54m | 1.27% |
| Unicorn Asset Management Ltd.as of 01 Jul 2024 | 3.97m | 1.11% |
| Legal & General Investment Management Ltd.as of 01 Jul 2024 | 3.74m | 1.04% |
| HSBC Bank Plc (Market-Maker)as of 01 Jul 2024 | 3.33m | 0.93% |
